There are no standardized effective treatment strategies for the condition. Current therapies for<unk>  are extrapolated from Cystic Fibrosis and patients with non-CF bronchiectasis and lack validation for<unk> -specific use. Severe fatal respiratory failure can develop; long-term treatment with macrolides such as clarithromycin, erythromycin and azithromycin has been empirically applied for the treatment of<unk>  in Japan, though controversial due to the effects of the medications.
Primary ciliary dyskinesia
Cystic fibrosis
Eustachian tube dysfunction
MOG antibody disease
Goldenhar syndrome
Oculopharyngeal muscular dystrophy
Adventitial cystic disease
Wolfram syndrome